与赤素相关的凝血功能障碍事件:来自FDA不良事件报告系统 (FAERS) 数据库的现实研究
Qian Cheng1, Ye Wu1, Zeyu Yao1
1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Thrombosis journal
|August 23, 2024
概括
第四代抗真菌药物埃奇诺坎丁与其他抗真菌药物相比,具有较高的凝血功能障碍风险. 对这些事件而言,安尼杜拉金的信号比米卡金和卡斯波金更为强烈.
科学领域:
- 药物监督 药物监督 药物监督
- 菌类学 菌类学是指菌类学.
- 血液学 血液学 血液学
背景情况:
- 埃奇诺坎丁是第四代抗真菌剂.
- 有限的系统研究存在于 echinocandins 和凝血功能障碍之间的关联.
- 这项研究旨在评估与echinocandin使用相关的凝血功能障碍风险.
研究的目的:
- 预测与 echinocandin 抗真菌药物相关的凝血功能障碍的风险.
- 为了比较 echinocandins 与其他抗真菌类 (triazoles, polyenes) 的风险信号.
- 为了比较不同等类动物 (caspofungin,micafungin,anidulafungin) 的风险信号.
主要方法:
- 从2004年1月到2024年3月的美国食品和药物管理局不良事件报告系统 (FAERS) 数据库中利用了数据.
- 分析了报告的凝血功能障碍事件的临床特征.
- 使用报告几率比率 (ROR) 进行了不成比例分析,以评估药物事件的关联.
主要成果:
- 鉴定了313份关于凝血功能障碍的报告,其中以赤甘丁作为主要的可疑药物.
- 与三醇和多相比, Echinocandins 在凝血功能障碍方面显示出更强烈的信号 (ROR 3.18).
- 安尼杜拉金显示出比卡斯波金和米卡金更强烈的信号 (ROR 6.84).
- 特定事件,如DIC,血小板减少和各种出血,与米卡金和卡斯波金有很强的关联.
结论:
- 埃奇诺坎丁对凝血功能障碍具有显著的信号,超过了三醇和多的信号.
- 与米卡丁和卡斯波丁相比,安尼杜拉丁表现出较高的凝血功能障碍风险信号.
- 建议在治疗期间密切监测凝血参数与这些echinocandin抗真菌药物.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
01:24Disorders of Hemostasis
756
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
756
01:09Coagulation
5.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
6.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.5K